COVID-19 treatment
-
July 22, 2020
Study to explore how COVID affects cognition over time
The Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University Medical Center is following patients who have been hospitalized for COVID-19 over time to see if they develop long-term cognitive impairment, depression or post-traumatic stress disorder (PTSD). -
July 22, 2020
New data offer insights on COVID treatments for people with cancer
Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population. -
July 16, 2020
Investigational glaucoma drug studied to prevent respiratory distress in COVID-19 patients
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. -
July 15, 2020
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. -
July 15, 2020
Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial
In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. -
July 9, 2020
New study supports remdesivir as COVID-19 treatment
This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus. -
July 9, 2020
Coordinated care network ensures COVID-positive patient makes recovery
On March 27, Nashville resident Bill Boyce, 73, earned the unwelcome distinction of becoming the first patient intubated on Vanderbilt University Medical Center’s dedicated COVID-19 unit.